Cargando…

Sorafenib in progressive castrate-resistant prostate cancer. Can we talk about a new therapeutic option?

Castrate-resistant prostate cancer represents a significant clinical challenge. Currently, the standard treatment for patients with castrate-resistant prostate cancer is chemotherapy, after which patients only receive symptomatic treatment. The available results of phase II clinical trials of sorafe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zaborowska, Magdalena, Szmit, Sebastian, Szczylik, Cezary
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2012
Materias:	State of the Art Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3400918/ https://www.ncbi.nlm.nih.gov/pubmed/22852011 http://dx.doi.org/10.5114/aoms.2012.29408

Ejemplares similares

Cardiac Biomarkers and Geriatric Assessment in Metastatic Castrate-Resistant Prostate Cancer During Abiraterone Acetate Therapy – A Cardio-Oncology Study
por: Wilk, Michał, et al.
Publicado: (2022)

Cardiovascular Disease in Chronic Kidney Disease: Pathophysiological Insights and Therapeutic Options
por: Jankowski, Joachim, et al.
Publicado: (2021)

Therapeutic options for severe asthma
por: Mathew, Jilcy, et al.
Publicado: (2012)

Psychiatric manifestations of neurologic disease: where are we headed?
por: Lyketsos, Constantin G., et al.
Publicado: (2007)

Nature and nurture in neuropsychiatric genetics: where do we stand?
por: Dick, Danielle M., et al.
Publicado: (2010)

Prediction of treatment outcomes in psychiatry—where do we stand ?
por: McMahon, Francis J.
Publicado: (2014)

The impact of the digital revolution  on human brain and behavior: where  do we stand? 
por: Korte, Martin
Publicado: (2020)

Active surveillance in prostate cancer management: where do we stand now?
por: Dragan, Jędrzej, et al.
Publicado: (2020)

The cardioprotective power of leaves
por: Dudzińska, Dominika, et al.
Publicado: (2015)

Game of “crowning” season 8: RAS and reproductive hormones in COVID-19 – can we end this viral series?
por: Cismaru, Andrei Cosmin, et al.
Publicado: (2020)

Help, hinder, hide and harm: what can we learn from the interactions between Pseudomonas aeruginosa and Staphylococcus aureus during respiratory infections?
por: Limoli, Dominique Hope, et al.
Publicado: (2019)

2023: The year in cardiovascular disease – the year of new and prospective lipid lowering therapies. Can we render dyslipidemia a rare disease by 2024?
por: Banach, Maciej, et al.
Publicado: (2023)

The role of vitamin D in perinatology. An up-to-date review
por: Ciebiera, Michał, et al.
Publicado: (2019)

Benefit–risk balance of native vitamin D supplementation in chronic hemodialysis: what can we learn from the major clinical trials and international guidelines?
por: Bentata, Yassamine
Publicado: (2019)

Therapeutic and Diagnostic Translation of Extracellular Vesicles in Cardiovascular Diseases: Roadmap to the Clinic
por: Sahoo, Susmita, et al.
Publicado: (2021)

Limitation of the therapeutic effort: ethical and legal justification for withholding and/or withdrawing life sustaining treatments
por: Borsellino, Patrizia
Publicado: (2015)

Immunosuppression in kidney transplant recipients with COVID-19 infection – where do we stand and where are we heading?
por: Daoud, Ahmed, et al.
Publicado: (2021)

MicroRNAs and metabolic disorders – where are we heading?
por: Sliwinska, Agnieszka, et al.
Publicado: (2017)

Myocardial viability testing: all STICHed up, or about to be REVIVED?
por: Ryan, Matthew, et al.
Publicado: (2021)

Ten things to know about ten cardiovascular disease risk factors
por: Bays, Harold E., et al.
Publicado: (2021)

Stroke and Bleeding Risk Assessment in Atrial Fibrillation: Where Are We Now?
por: Kuo, Ling, et al.
Publicado: (2021)

Imaging subclinical coronary atherosclerosis to guide lipid management, are we there yet?
por: Piña, Pamela, et al.
Publicado: (2022)

Ten things to know about ten cardiovascular disease risk factors – 2022
por: Bays, Harold E, et al.
Publicado: (2022)

Dampening antiviral immunity can protect the host
por: Panetti, Camilla, et al.
Publicado: (2021)

What We Talk About When We Talk About Evolution
por: Torday, John S.
Publicado: (2015)

What We Talk About When We Talk About Light
por: Forbes, Malcolm D. E.
Publicado: (2015)

What we talk about when we talk about colors
por: Twomey, Colin R., et al.
Publicado: (2021)

Cardiac microRNAs: diagnostic and therapeutic potential
por: Kabłak-Ziembicka, Anna, et al.
Publicado: (2023)

Ten things to know about ten cardiovascular disease risk factors (“ASPC Top Ten – 2020”)
por: Bays, Harold Edward
Publicado: (2020)

Optimizing Foundational Therapies in Patients With HFrEF: How Do We Translate These Findings Into Clinical Care?
por: Sharma, Abhinav, et al.
Publicado: (2022)

Glomerular diseases after immune checkpoint inhibitors use: What do We know so far?
por: He, Xue, et al.
Publicado: (2022)

Emergent processes in cognitive-emotional interactions
por: Pessoa, Luiz
Publicado: (2010)

Bipolar disorder
por: Goodwin, Frederick K., et al.
Publicado: (1999)

Depression in late life
por: Barry, D. Lebowitz
Publicado: (1999)

The treatment of schizophrenia: from premorbid manifestations to the first episode of psychosis
por: Davidson, Michael, et al.
Publicado: (2005)

Genetic bases for endophenotypes in psychiatric disorders
por: Berrettini, Wade H.
Publicado: (2005)

The pharmacological management of depression
por: Kupfer, David J.
Publicado: (2005)

Sleep and psychiatry
por: Abad, Vivien C., et al.
Publicado: (2005)

Various forms of depression
por: Benazzi, Franco
Publicado: (2006)

Chronobiology and mood disorders
por: Wirz-Justice, Anna
Publicado: (2003)

Cannot write session to /tmp/vufind_sessions/sess_svv8jdasu38nvtgrg7hsa6lkv3